1 / 22

Chondrosarcoma

GDC-0449 in Patients With Advanced Chondrosarcomas: a French Sarcoma Group / French and US NCI phase II collaborative study.

terra
Download Presentation

Chondrosarcoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GDC-0449 in Patients With Advanced Chondrosarcomas: a French Sarcoma Group/Frenchand US NCI phase II collaborative study Antoine Italiano, Axel Le Cesne, Jean-Yves Blay, Sophie Piperno-Neumann, Florence Duffaud, Nicolas Penel, Philippe Cassier, Julien Domont, Naoko Takebe, Carine Bellera, Binh Bui

  2. Chondrosarcoma • Chondrosarcoma is the most common primary malignancy of bone in adults. • Localized disease: surgery ++ • Locally unresectable/metastatic disease: conventional cytotoxic agents and radiotherapy are generally considered as not effective.

  3. Hedgehog pathway Four mechanims of activation • mutation driven: baselcellcarcinoma, medulloblastoma • autonomoustumorcell activation • Stroma supporting • Cancer stem cell

  4. Hedgehog pathway is overexpressed in chondrosarcomas Tiet TD et al. Am J Pathol 2006;168(1):321-30.

  5. Hedgehog: a crucial pathway in chondrosarcomas Inhibition of the hedgehog pathway in chondrosarcoma xenografts results in reduced cell proliferation and decreased tumor size Tiet TD et al. Am J Pathol 2006;168(1):321-30.

  6. SMO inhibitors have preclinical activity in chondrosarcomas Campbell et al. AACR 2011 abstract number LB-380

  7. GDC-0449 (Vismodegib) background • GDC-0449 is a selective Hh pathway inhibitor that blocks Hh signaling by binding to SMO and inhibiting activation of downstream Hh target genes • Preclinical activity in several tumor models: medulloblastoma, colorectal cancer, pancreatic carcinoma… • FDA approved on Jan. 30 2012 for the treatment of adults with metastatic basal cell carcinoma or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

  8. COLLABORATION

  9. Study aim and endpoints • Aim: To assess the efficacy and safety of GDC-0449 in patients with locally advanced (unresctable) and/or metastatic chondrosarcomas • First endpoint: • 6-months clinical benefit rate (CR, PR and SD as per RECIST criteria, based on centralized review) • Secondary endpoints: • Objective response rate (RECIST) • Best overall response (RECIST) • 1-year and 2-year progression-free survival • 1-year and 2-year overall survival • Safety • Biomarkers: PTCH and SMO sequencing PTCH, SMO, GLI1 expression (qRT-PCR)

  10. Study design Single-arm phase 2 clinical trial based on two-stage Simon’s design. Study population: Adult patients with unresectable locally advanced or metastatic chondrosarcoma (with confirmation of histology based on centralized review) GDC-0449: 150 mg, take with or without food at the same time every day (day 1-day 28) Radiological tumor assessment performed at baseline and every eight weeks Centralized histological and radiological review

  11. Statistical hypothesis • No chemotherapy historical series to build a statistical hypothesis • Based on the following hypotheses: • H0: 20% 6-month non-progression rate • H1: 40% 6-month non-progression rate • 10% type I error rate + 90% power  37 eligible and assessable patients required. • Stage 1: 17 patients (4/17 non-prog required to continue) • Stage 2 : 20 patients (11/37 non-prog required to claim efficacy) • 45 patients recruited to account for not assessable patients

  12. Patient disposition* *A the time of analysis: October 17th, 2012

  13. Baseline Characteristics *with centralized review)

  14. Efficacy: First endpoint • 11 patients out of 37 achieved stable disease at 6-months after central radiological review • Clinical benefit rate: 29.7% (95% CI,15.9- 47.0) Studyachieveditsprimaryendpoint

  15. Male 80 years GDC-0449 start: 11/2011 Still under treatment (11/2012) RECIST: SD (0%) DCE-MRI: partial response

  16. Efficacy: Progression-Free Survival Median PFS: 3.6 months (95% CI, 1.9-5.5) 6-months PFS: 32.4% (95% CI,18.2-47.5) 1-year PFS: 22.5% (95% CI, 10.1-37.9)

  17. Efficacy: Overall Survival Median OS: 12.4 months 6-months OS: 79.1% (95% CI, 62.4-88.9) 1-year OS: 52.6 % (95% CI, 33.8-68.3)

  18. Adverse events* (N=45 treated patients) *Related to the treatment)

  19. Exploratory analysis (N=40) All patients with 6-months clinical benefit have grade 1 or 2 conventional chondrosarcoma

  20. Translational study No mutation of PTCH and SMO Overexpression of HH ligand in 65% of cases No significant correlation between HH, GLI1, GLI2 gene expression and outcome (Wilcoxon two-sample test)

  21. International academic collaboration is feasible in the context of rare cancer GDC-0449 is well tolerated with limited dysguesia, alopecia and myalgia being the most frequent adverse events GDC-0449 is associated with long-term stable disease in a subset of patients with advanced chondrosarcoma Conclusion

  22. The authors would like to thank: the patients and their families the investigators and staff at the participating centers Study funded by the French National Cancer Institute Acknowledgements

More Related